S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:FBIO

Fortress Biotech - FBIO Stock Forecast, Price & News

$1.27
-0.02 (-1.55%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.25
$1.33
50-Day Range
$0.80
$1.29
52-Week Range
$0.77
$3.81
Volume
341,390 shs
Average Volume
585,486 shs
Market Capitalization
$136.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

Fortress Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
655.9% Upside
$9.60 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Fortress Biotech in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.72) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

185th out of 1,117 stocks

Pharmaceutical Preparations Industry

83rd out of 550 stocks

FBIO stock logo

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Fortress Biotech Price Performance

NASDAQ:FBIO traded down $0.02 during trading hours on Friday, reaching $1.27. 341,390 shares of the stock traded hands, compared to its average volume of 585,486. The company has a market cap of $136.41 million, a price-to-earnings ratio of -1.50 and a beta of 2.10. The stock has a 50 day simple moving average of $0.93 and a two-hundred day simple moving average of $1.21. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.31 and a quick ratio of 3.15. Fortress Biotech has a 1 year low of $0.77 and a 1 year high of $3.81.

Fortress Biotech (NASDAQ:FBIO - Get Rating) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.10. The firm had revenue of $23.93 million for the quarter, compared to the consensus estimate of $20.06 million. Fortress Biotech had a negative return on equity of 32.56% and a negative net margin of 88.31%. During the same quarter in the previous year, the business earned ($0.11) earnings per share. On average, analysts predict that Fortress Biotech will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on FBIO. StockNews.com upgraded Fortress Biotech from a "sell" rating to a "hold" rating in a research report on Thursday, May 19th. Cantor Fitzgerald reiterated a "buy" rating and issued a $6.00 price objective on shares of Fortress Biotech in a research report on Friday, May 13th. LADENBURG THALM/SH SH began coverage on Fortress Biotech in a research report on Thursday, August 4th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, B. Riley lowered their price objective on Fortress Biotech from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Thursday, July 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $9.60.

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

Fortress Biotech, Inc. (FBIO)
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings
11/15/2021
Today
8/12/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.60
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+655.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-64,700,000.00
Pretax Margin
-231.44%

Debt

Sales & Book Value

Annual Sales
$68.79 million
Book Value
$2.27 per share

Miscellaneous

Free Float
79,163,000
Market Cap
$136.41 million
Optionable
Optionable
Beta
2.10

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 67)
    Exec. Chairman, Pres & CEO
    Comp: $92.65k
  • Mr. Michael S. Weiss Esq. (Age 56)
    Vice Chairman & Exec. Vice Chairman of Strategic Devel.
    Comp: $92.65k
  • Ms. Robyn M. Hunter (Age 60)
    CFO, Treasurer & Corp. Sec.
    Comp: $555.31k
  • Dr. George C. Avgerinos (Age 68)
    Sr. VP of Biologics Operations
    Comp: $524.35k
  • Dr. Thomas F. Schaible
    Project Leader of Inflammatory Bowel Disease













FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings
or view top-rated stocks.

What is Fortress Biotech's stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month price objectives for Fortress Biotech's stock. Their FBIO share price forecasts range from $6.00 to $20.00. On average, they expect the company's stock price to reach $9.60 in the next twelve months. This suggests a possible upside of 655.9% from the stock's current price.
View analysts price targets for FBIO
or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2022?

Fortress Biotech's stock was trading at $2.50 at the beginning of the year. Since then, FBIO shares have decreased by 49.2% and is now trading at $1.27.
View the best growth stocks for 2022 here
.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our FBIO earnings forecast
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) issued its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. The biopharmaceutical company earned $21.09 million during the quarter, compared to the consensus estimate of $18.41 million. Fortress Biotech had a negative trailing twelve-month return on equity of 32.56% and a negative net margin of 88.31%.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Shikiar Asset Management Inc. (0.74%), Perkins Capital Management Inc. (0.71%), Sepio Capital LP (0.06%), Connor Clark & Lunn Investment Management Ltd. (0.05%) and BNP Paribas Arbitrage SA (0.04%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends
.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $1.27.

How much money does Fortress Biotech make?

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $136.41 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Fortress Biotech have?

The company employs 173 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.